SCHEMBL9894355

SCHEMBL9894355

CNC(=O)c1nc(-c2ccccc2)n(-c2cccc(Cl)c2)c1-c1cccc(Cl)c1F

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 5/20 0.56
RIPK1 Q13546 2/20 0.43
PDE4A P27815 3/20 0.41
PDE4B Q07343 3/20 0.41
PDE4C Q08493 3/20 0.41
PDE4D Q08499 3/20 0.41
POLB P06746 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
GRM5 P41594 1/20 0.39
PAK1 Q13153 1/20 0.39
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
PLK1 P53350 1/20 0.38
NUDT1 P36639 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1437201 0.89 MDM2 (0.53) MDM2RIPK1PDE4APDE4BPDE4C
SCHEMBL1442682 0.88 MDM2 (0.72) MDM2RIPK1GABRA2GABRB2MGAM
SCHEMBL27862823 0.88 MDM2 (0.56) MDM2RIPK1POLBRXFP1GABRA2
SCHEMBL1437198 0.88 MDM2 (0.54) MDM2PDE4APDE4BPDE4CPDE4D
SCHEMBL9893773 0.86 MDM2 (0.76) MDM2POLBRXFP1GABRA2GABRB2
SCHEMBL1437159 0.85 MDM2 (0.61) MDM2RIPK1PDE4APDE4BPDE4C
SCHEMBL1436800 0.84 MDM2 (0.78) MDM2RIPK1PDE4APDE4BPDE4C
SCHEMBL1437056 0.84 MDM2 (0.64) MDM2PDE4APDE4BPDE4CPDE4D
SCHEMBL1440068 0.84 MDM2 (0.57) MDM2GABRA2GABRB2
SCHEMBL1438008 0.84 MDM2 (0.69) MDM2POLBRXFP1GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885RIPK1 2376/4885PDE4A 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.